Cyclic opioid peptides

Michael Remesic, Yeon Sun Lee, Victor J Hruby

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

For decades the opioid receptors have been an attractive therapeutic target for the treatment of pain. Since the first discovery of enkephalin, approximately a dozen endogenous opioid peptides have been known to produce opioid activity and analgesia, but their therapeutics have been limited mainly due to low blood brain barrier penetration and poor resistance to proteolytic degradation. One versatile approach to overcome these drawbacks is the cyclization of linear peptides to cyclic peptides with constrained topographical structure. Compared to their linear parents, cyclic analogs exhibit better metabolic stability, lower offtarget toxicity, and improved bioavailability. Extensive structure-activity relationship studies have uncovered promising compounds for the treatment of pain as well as further elucidate structural elements required for selective opioid receptor activity. The benefits that come with employing cyclization can be further enhanced through the generation of polycyclic derivatives. Opioid ligands generally have a short peptide chain and thus the realm of polycyclic peptides has yet to be explored. In this review, a brief history of designing ligands for the opioid receptors, including classic linear and cyclic ligands, is discussed along with recent approaches and successes of cyclic peptide ligands for the receptors. Various scaffolds and approaches to improve bioavailability are elaborated and concluded with a discourse towards polycyclic peptides.

Original languageEnglish (US)
Pages (from-to)1288-1303
Number of pages16
JournalCurrent Medicinal Chemistry
Volume23
Issue number13
StatePublished - Apr 1 2016

Fingerprint

Cyclic Peptides
Opioid Peptides
Opioid Receptors
Ligands
Peptides
Cyclization
Opioid Analgesics
Biological Availability
Pain
Peptide Receptors
Enkephalins
Therapeutics
Structure-Activity Relationship
Blood-Brain Barrier
Scaffolds
Analgesia
Toxicity
Derivatives
Degradation

Keywords

  • Analgesia
  • Bioavailability
  • Blood brain barrier penetration
  • Central nervous system
  • Cyclic peptides
  • Opioid receptors
  • Polycyclic

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Remesic, M., Lee, Y. S., & Hruby, V. J. (2016). Cyclic opioid peptides. Current Medicinal Chemistry, 23(13), 1288-1303.

Cyclic opioid peptides. / Remesic, Michael; Lee, Yeon Sun; Hruby, Victor J.

In: Current Medicinal Chemistry, Vol. 23, No. 13, 01.04.2016, p. 1288-1303.

Research output: Contribution to journalReview article

Remesic, M, Lee, YS & Hruby, VJ 2016, 'Cyclic opioid peptides', Current Medicinal Chemistry, vol. 23, no. 13, pp. 1288-1303.
Remesic M, Lee YS, Hruby VJ. Cyclic opioid peptides. Current Medicinal Chemistry. 2016 Apr 1;23(13):1288-1303.
Remesic, Michael ; Lee, Yeon Sun ; Hruby, Victor J. / Cyclic opioid peptides. In: Current Medicinal Chemistry. 2016 ; Vol. 23, No. 13. pp. 1288-1303.
@article{b17eee5b2f5d4f49a6d34b0f5be3fc1d,
title = "Cyclic opioid peptides",
abstract = "For decades the opioid receptors have been an attractive therapeutic target for the treatment of pain. Since the first discovery of enkephalin, approximately a dozen endogenous opioid peptides have been known to produce opioid activity and analgesia, but their therapeutics have been limited mainly due to low blood brain barrier penetration and poor resistance to proteolytic degradation. One versatile approach to overcome these drawbacks is the cyclization of linear peptides to cyclic peptides with constrained topographical structure. Compared to their linear parents, cyclic analogs exhibit better metabolic stability, lower offtarget toxicity, and improved bioavailability. Extensive structure-activity relationship studies have uncovered promising compounds for the treatment of pain as well as further elucidate structural elements required for selective opioid receptor activity. The benefits that come with employing cyclization can be further enhanced through the generation of polycyclic derivatives. Opioid ligands generally have a short peptide chain and thus the realm of polycyclic peptides has yet to be explored. In this review, a brief history of designing ligands for the opioid receptors, including classic linear and cyclic ligands, is discussed along with recent approaches and successes of cyclic peptide ligands for the receptors. Various scaffolds and approaches to improve bioavailability are elaborated and concluded with a discourse towards polycyclic peptides.",
keywords = "Analgesia, Bioavailability, Blood brain barrier penetration, Central nervous system, Cyclic peptides, Opioid receptors, Polycyclic",
author = "Michael Remesic and Lee, {Yeon Sun} and Hruby, {Victor J}",
year = "2016",
month = "4",
day = "1",
language = "English (US)",
volume = "23",
pages = "1288--1303",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Cyclic opioid peptides

AU - Remesic, Michael

AU - Lee, Yeon Sun

AU - Hruby, Victor J

PY - 2016/4/1

Y1 - 2016/4/1

N2 - For decades the opioid receptors have been an attractive therapeutic target for the treatment of pain. Since the first discovery of enkephalin, approximately a dozen endogenous opioid peptides have been known to produce opioid activity and analgesia, but their therapeutics have been limited mainly due to low blood brain barrier penetration and poor resistance to proteolytic degradation. One versatile approach to overcome these drawbacks is the cyclization of linear peptides to cyclic peptides with constrained topographical structure. Compared to their linear parents, cyclic analogs exhibit better metabolic stability, lower offtarget toxicity, and improved bioavailability. Extensive structure-activity relationship studies have uncovered promising compounds for the treatment of pain as well as further elucidate structural elements required for selective opioid receptor activity. The benefits that come with employing cyclization can be further enhanced through the generation of polycyclic derivatives. Opioid ligands generally have a short peptide chain and thus the realm of polycyclic peptides has yet to be explored. In this review, a brief history of designing ligands for the opioid receptors, including classic linear and cyclic ligands, is discussed along with recent approaches and successes of cyclic peptide ligands for the receptors. Various scaffolds and approaches to improve bioavailability are elaborated and concluded with a discourse towards polycyclic peptides.

AB - For decades the opioid receptors have been an attractive therapeutic target for the treatment of pain. Since the first discovery of enkephalin, approximately a dozen endogenous opioid peptides have been known to produce opioid activity and analgesia, but their therapeutics have been limited mainly due to low blood brain barrier penetration and poor resistance to proteolytic degradation. One versatile approach to overcome these drawbacks is the cyclization of linear peptides to cyclic peptides with constrained topographical structure. Compared to their linear parents, cyclic analogs exhibit better metabolic stability, lower offtarget toxicity, and improved bioavailability. Extensive structure-activity relationship studies have uncovered promising compounds for the treatment of pain as well as further elucidate structural elements required for selective opioid receptor activity. The benefits that come with employing cyclization can be further enhanced through the generation of polycyclic derivatives. Opioid ligands generally have a short peptide chain and thus the realm of polycyclic peptides has yet to be explored. In this review, a brief history of designing ligands for the opioid receptors, including classic linear and cyclic ligands, is discussed along with recent approaches and successes of cyclic peptide ligands for the receptors. Various scaffolds and approaches to improve bioavailability are elaborated and concluded with a discourse towards polycyclic peptides.

KW - Analgesia

KW - Bioavailability

KW - Blood brain barrier penetration

KW - Central nervous system

KW - Cyclic peptides

KW - Opioid receptors

KW - Polycyclic

UR - http://www.scopus.com/inward/record.url?scp=84974527991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974527991&partnerID=8YFLogxK

M3 - Review article

C2 - 27117332

AN - SCOPUS:84974527991

VL - 23

SP - 1288

EP - 1303

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 13

ER -